Nightingale Health Oyj Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Nightingale Health Oyj şirketinin toplam hissedar öz sermayesi €82.9M ve toplam borcu €827.0K olup, bu da borç-öz sermaye oranını 1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €90.8M ve €8.0M dir.

Anahtar bilgiler

1.0%

Borç/özkaynak oranı

€827.00k

Borç

Faiz karşılama oranı	n/a
Nakit	€66.04m
Eşitlik	€82.88m
Toplam yükümlülükler	€7.96m
Toplam varlıklar	€90.84m

Son finansal sağlık güncellemeleri

Does Nightingale Health Oyj (HEL:HEALTH) Have A Healthy Balance Sheet?

May 03

Recent updates

Does Nightingale Health Oyj (HEL:HEALTH) Have A Healthy Balance Sheet?

May 03

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: HEALTH 'nin kısa vadeli varlıkları ( €68.4M ) kısa vadeli yükümlülüklerini ( €7.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: HEALTH şirketinin kısa vadeli varlıkları ( €68.4M ) uzun vadeli yükümlülüklerini ( €1.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: HEALTH şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: HEALTH 'nin borç/öz sermaye oranı son 5 yılda 126.9% seviyesinden 1% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: HEALTH şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: HEALTH, serbest nakit akışı her yıl % 12.5 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

Nightingale Health Oyj Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Does Nightingale Health Oyj (HEL:HEALTH) Have A Healthy Balance Sheet?

Recent updates

Nightingale Health Appoints Dr. Charles Alessi as Chief Medical Officer of Nightingale Health UK

Consensus revenue estimates fall by 25%

Nightingale Health Oyj, Annual General Meeting, Nov 08, 2024

Full year 2024 earnings: Revenues miss analyst expectations

Nightingale Health Receives Third Regulatory Approval for Healthcare Use from Health Sciences Authority in Singapore

Nightingale Health Attains UKCA Marking for its Blood Analysis Technology to Bring Its Technology to Healthcare Use in the United Kingdom

Does Nightingale Health Oyj (HEL:HEALTH) Have A Healthy Balance Sheet?

First half 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to €0.27 loss, revenue downgraded

Nightingale Health Oyj to Report First Half, 2024 Results on Mar 07, 2024

Nightingale Health Oyj Receives Regulatory Approval for Healthcare Use from Health Sciences Authority in Singapore

Nightingale Health plc Receives Five New Patents for Its Proprietary Health Risk Detection Capability

Nightingale Health Completes the Analysis of All 500,000 UK Biobank Samples Creating the Largest Blood Biomarker Database for Chronic Disease Research and Prevention

Nightingale Health plc Announces Maximilian Leroux Leaves as Chief Commercial Officer

Nightingale Health plc Announces Maximilian Leroux Leaves as Chief Commercial Officer

Full year 2023 earnings: Revenues miss analyst expectations

Nightingale Health Receives Three New Patents Further Strengthening Its IP Portfolio

Nightingale Health Rolls Out Remote Blood Collection Kit for Medical Research and Clinical Trials

Nightingale Health plc Announces Population Study Combining Blood Biomarkers and Genetics Demonstrates

Nightingale Health plc Announces Biomarker Results of Additional 200,000 Blood Samples Soon Available to Researchers Globally

Nightingale Health Oyj to Report Fiscal Year 2023 Results on Sep 28, 2023

Nightingale Health Receives Six Patent Approvals for Its Proprietary Health Risk Detection Platform

Nightingale Health Appoints Maximilian LeRoux as Chief Commercial Officer, Effective August 1, 2023

First half 2023 earnings: EPS in line with analyst expectations despite revenue beat

Consensus revenue estimates increase by 48%, EPS downgraded

Nightingale Health Oyj to Report First Half, 2023 Results on Mar 23, 2023

Price target decreased to €1.40

Full year 2022 earnings: Revenues miss analyst expectations

Nightingale Health Oyj to Report Q4, 2022 Results on Oct 27, 2022

Nightingale Health Oyj to Report First Half, 2023 Results on Mar 02, 2023

Price target decreased to €4.00

Nightingale Health Launches Consumer Service Livit by Nightingale Health Utilizing Its At-Home Testing Solution

Consensus forecasts updated

Nightingale Health Oyj to Report Q2, 2022 Results on Feb 24, 2022

Nightingale Health Oyj (HLSE:HEALTH) completed the acquisition of Negen Oy.

Nightingale Health Oyj (HLSE:HEALTH) agreed to acquire Negen Ltd.

Full year 2021 earnings released: €0.27 loss per share (vs €0.085 loss in FY 2020)

Nightingale Health Oyj Successfully Completes the First Phase of Its At-Home Blood Testing Pilot

Chief Product Officer has left the company

Nightingale Health Oyj has completed an IPO in the amount of €137.499998 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin